Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2005-08-10
2009-11-17
Ulm, John D. (Department: 1649)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C514S001000, C424S400000, C424S001650
Reexamination Certificate
active
07618615
ABSTRACT:
Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke.
REFERENCES:
patent: 5624898 (1997-04-01), Frey, II
patent: 5849290 (1998-12-01), Brown et al.
patent: 6313093 (2001-11-01), Frey, II
patent: 2003/0072973 (2003-04-01), Frey, II et al.
patent: 2004/0101521 (2004-05-01), Andersen
patent: 2004/0167217 (2004-08-01), Scapagnini et al.
patent: WO 91/07947 (1991-06-01), None
Wang and Semenza, Blood, 82(12): 3610-3615, Dec. 15, 1993.
Kumat et al., J. Alzheimer's Dis., 15(3):473-493, Nov. 2008.
King RG, Med J Aust, 142(6; 352, Mar. 18, 1985.
Kruck et al., Clin Pharmacol Ther, 48(4): 439-446, Oct. 1990.
Gordon et al., Amer J Med Sci, 297(5): 280-284, May 1989.
Metals in our minds: therapeutic implications for neurodegenerative disorders, P. Murali Doraiswamy and Anne E. Finefrock, The LANCET Neurology vol. 3, Jul. 2004 (pp. 431-434).
Delivery of Insulin-Like Growth Factor-I to the Rat Brain and Spinal Cord Along Olfactory and Trigeminal Pathways Following Intranasal Administration, R.G. Thorne, et al., Neuroscience 127 (2004) (pp. 481-496).
Maxwell and Salniknow, Cancer Biology and Therapy 3(1): 29-35. (Jan. 2004).
Brenneisen et al., The Journal of Biological Chemistry 273(9): 5279-5287. (Feb. 27, 1998).
Crapper McLachlan et al., Lancet 337(8753): 1304-1308. (Jun. 1, 1991).
Chaston and Richardson, American Journal of Hematology 73: 200-210. (2003).
Frey, II William H.
Hanson Leah Ranae Bresin
Panter Samual Scott
Altera Law Group LLC
HealthPartners Research Foundation
MacFarlane Stacey
Ulm John D.
LandOfFree
Methods for providing neuroprotection for the animal central... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for providing neuroprotection for the animal central..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for providing neuroprotection for the animal central... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090368